Home › Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine
 

Keywords :   


Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine

2013-05-23 23:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language:  English Contact HTML:  MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: program iii update medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Post Office minister 'horrified' at more IT faults
30.09PPGs SEM Products Business Launches Performance Abrasives Product Line
30.09Pulse demonstrates Monolox at Mark Andy Poland workshop
30.09EMT International names John Pecoraro regional sales manager
30.09IDENTCO chosen by watercraft provider for label durability
30.09New Product Line: MIPA Combines Quality with Sustainability
30.09HiFlow Solutions appoints Alfonso Hernandez, Jr. VP of sales
30.09Tropical Storm Kirk Graphics
More »